Étiquette : legal highs

New psychoactive substances: a review and updates, Abu Shafi et al., 2020

New psychoactive substances: a review and updates Abu Shafi, Alex J. Berry, Harry Sumnall, David M. Wood and Derek K. Tracy Therapeutic Advances in Psychopharmacology, 2020, Vol. 10, 1–21. Doi : 10.1177/2045125320967197   Abstract : New psychoactive substances (NPS) are a heterogeneous group of substances. They are associated with a number of health and social harms on an individual and societal level. NPS toxicity and dependence syndromes are recognised in primary care, emergency departments, psychiatric inpatient and community care settings. One pragmatic classification system is to divide NPS into one of four groups: synthetic stimulants, synthetic cannabinoids, synthetic hallucinogens and synthetic depressants (which include synthetic opioids [...]

Lire la suite

Les nouveaux produits de synthèse, MILDECA, 2015

Les nouveaux produits de synthèse Publié le 10/08/2015 https://www.drogues.gouv.fr/comprendre/ce-qu-il-faut-savoir-sur/les-nouveaux-produits-de-synthese Les « nouveaux produits de synthèse » couramment appelés ainsi, portent officiellement le nom de « nouvelles substances psychoactives » (ONU et Union Européenne) car derrière cette appellation existent des substances psychoactives à la fois d’origine naturelle et synthétique. La plupart sont fabriquées en laboratoire, d’où leur appellation de « nouveaux produits de synthèse », voire, en anglais, de « research chemicals » (RC) ou de « designer drugs ». Certaines imitent les effets du cannabis, d’autres les effets de la cocaïne, de la MDMA / ecstasy ou des amphétamines. La première spécificité d’un certain nombre de ces substances est [...]

Lire la suite

Clinical and Toxicological Profile of NBOMes : A Systematic Review, Nino Cesar Marchi et al., 2019

Clinical and Toxicological Profile of NBOMes : A Systematic Review Nino Cesar Marchi, Juliana Nichterwitz Scherer, Letícia Schwanck Fara, Lysa Remy, Rafaela Ornel, Monique Reis, Amanda Zamboni, Mariana Paim, Taís Regina Fiorentin, Carlos Alberto Yasin Wayhs, Lisia Von Diemen, Flavio Pechansky, Felix Henrique Paim Kessler, Renata Pereira Limberger Psychosomatics, 2019 Mar - Apr, 60, (2), 129-138. doi : 10.1016/j.psym.2018.11.002   Background : NBOMes are a new class of potent hallucinogens widely present in illicit drugs. Little is known about this class of drugs, regarding its detection and clinical manifestations of intoxication. Objective : This study aims to enhance care involving NBOMes by reviewing the literature on their [...]

Lire la suite

Legal highs : staying on top of the flood of novel psychoactive substances, David Baumeister et al., 2015

Legal highs : staying on top of the flood of novel psychoactive substances David Baumeister, Luis M. Tojo and Derek K. Tracy Therapeutic Advances in Psychopharmacology, 2015, Vol. 5, (2), 97–132 DOI: 10.1177/2045125314559539   Abstract : There has been growing clinical, public, and media awareness and concern about the availability and potential harmfulness of so-called ‘legal highs’, which are more appropriately called new or novel psychoactive substances (NPS). A cat-and-mouse process has emerged wherein unknown chemists and laboratories are producing new, and as yet nonproscribed, compounds for human consumption; and as soon as they are banned, which they inevitably are, slightly modified analogues are produced to [...]

Lire la suite